Paraoxonase in women with hypertension of different reproductive age. Relationship with cardio-metabolic risk factors


Keywords: paraoxonase, homocysteine, cholesterol, hypertension, menopause.

Abstract

Annotation. Paraoxonase is a high-density lipoprotein-associated pleiotropic enzyme able to detoxify proatherogenic compounds such as oxi-low-density-lipoproteins and homocysteine-thiolactone. Low paraoxonase activity is likely to be involved in the development of cardiovascular diseases. The aim of the study – to investigate the relationship between paraoxonase activity, structural and functional markers of the heart and blood vessels, cardio-metabolic risk factors in women with hypertension of different reproductive age. The study included 193 women aged 32-70 years (55.4±0.68 years) with essential stage II hypertension. The control group consisted of 46 healthy women. The arylesterase activity of paraoxonase (EC 3.1.1.2) in blood serum was determined by spectrophotometric method. Statistical processing of the obtained results was performed in the application package SPSS22 (© SPSS Inc.). The mean and standard error of the mean (M ± m) were calculated. Student's t-test was used. Pearson correlation analysis was performed at p <0.05. It was found that in women with hypertension there was a significant decrease (16%) in serum paraoxonase activity, compared with healthy women. Low paraoxonase activity was registered in 33.3% of premenopausal patients and 56.7% of postmenopausal patients (p˂0.05) and was associated with serum estradiol levels (r=0.33, 0.41, p<0.05). Low paraoxonase activity was associated with aberrant levels of lipids, homocysteine, obesity, metabolic syndrome, increased left ventricular mass index and carotid intima-media thickness, decreased brachial artery endothelium-dependent vasodilation. Thus, the decrease in serum paraoxonase activity in women with hypertension is related with the reproductive age of patients and the development of unfavorable metabolic, structural and functional changes in the heart and blood vessels.

References

[1] Ahmad, S., & Scott, J. E. (2010). Estradiol enhances cell-associated paraoxonase 1 (PON1) activity in vitro without altering PON1 expression. Biochem Biophys Res Commun., 397, 441-446. DOI: 10.1016/j.bbrc.2010.05.120

[2] Ambikairajah, A., Walsh, E., & Cherbuin, N. (2019). Lipid profile differences during menopause: a review with meta-analysis. Menopause, 26(11), 1327-1333. DOI: 10.1097/GME.0000000000001403

[3] Bahtiri, E., Islami, H., Rexhepi, S., Qorraj-Bytyqi, H., Thaçi, K., Thaçi, S., … & Hoxha, R. (2015). Relationship of homocysteine levels with lumbar spine and femur neck BMD in postmenopausal women. Acta Reumatol Port, 40(4), 355-362.

[4] Blacher, J., Kretz, S., Sorbets, E., Lelong, H., Vallée, A., & Lopez-Sublet, M. (2019). Epidemiology of hypertension: Differences between women and men. Presse Med., 48(11 Pt 1), 1240-1243. DOI: 10.1016/j.lpm.2019.04.010

[5] Celermajer, D., & Sorensen, K. (1992). Noninvasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet, 340, 1111-1115. DOI: 10.1016/0140-6736(92)93147-f

[6] Cheng, X., & Klaassen, C. D. (2012). Hormonal and chemical regulation of paraoxonases in mice. J Pharm Exp., 342, 688-695. DOI: 10.1124/jpet.112.194803

[7] Chernyavskiy, I., Veeranki, S., Sen, U., & Tyagi, S. C. (2016). Atherogenesis: hyperhomocysteinemia interactions with LDL, macrophage function, paraoxonase 1, and exercise. Ann N Y Acad Sci., 1363(1), 138-154. DOI:10.1111/nyas.13009

[8] Chistiakov, D. A., Melnichenko, A. A., Orekhov, A. N., & Bobryshev, Y. V. (2017). Paraoxonase and atherosclerosis-related cardiovascular disease. Biochimie, 132, 19-27. DOI: 10.1016/j.biochi.2016.10.010

[9] Connelly, P. W., Maguire, G. F., & Draganov, D. I. (2004). Separation and quantitative recovery of mouse serum arylesterase and carboxylesterase activity. J Lipid Res., 45(3), 561-566. DOI: 10.1194/jlr.M300464-JLR200

[10] Dounousi, E., Bouba, I., Spoto, B., Pappas, K., Tripepi, G., Georgiou, I., … & Siamopoulos, K. (2016). A Genetic Biomarker of Oxidative Stress, the Paraoxonase-1 Q192R Gene Variant, Associates with Cardiomyopathy in CKD: A Longitudinal Study. Oxid Med Cell Longev., 2016, 1507270. DOI: 10.1155/2016/1507270

[11] Fu, Y., Wang, X., & Kong, W. (2018). Hyperhomocysteinaemia and vascular injury: advances in mechanisms and drug targets. British Journal of Pharmacology, 175(8), 1173-1189. DOI: 10.1111/bph.13988

[12] Goossens, G. H., Jocken, J. W. E., & Blaak, E. E. (2021). Sexual dimorphism in cardiometabolic health: the role of adipose tissue, muscle and liver. Nat Rev Endocrinol., 17(1), 47-66. DOI: 10.1038/s41574-020-00431-8

[13] Harlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., Rebar, R. W., … & de Villiers, T. J. (2012). Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause, 19(4), 387-95. DOI: 10.1097/gme.0b013e31824d8f40

[14] Jiang, Q., Wang, L., Si, X., Tian, J. L., Zhang, Y., Gui, H. L., … & Tan, D. H. (2021). Current progress on the mechanisms of hyperhomocysteinemia-induced vascular injury and use of natural polyphenol compounds. Eur J Pharmacol., 905, 174168. DOI: 10.1016/j.ejphar.2021.174168

[15] Ko, S. H., & Kim, H. S. (2020). Menopause-Associated Lipid Metabolic Disorders and Foods Beneficial for Postmenopausal Women. Nutrients, 12(1), 202. DOI: 10.3390/nu12010202

[16] Medina, D., Mehay, D., & Arnold, A. C. (2020). Sex differences in cardiovascular actions of the renin-angiotensin system. Clin Auton Res., 30(5), 393-408. DOI: 10.1007/s10286-020-00720-2

[17] Novella, S., Pérez-Cremades, D., Mompeó, A., & Hermenegildo, C. (2019). Mechanisms underlying the influence of oestrogen on cardiovascular physiology in women. J Physiol., 597(19), 4873-4886. DOI: 10.1113/JP278063

[18] Perła-Kaján, J., & Jakubowski, H. (2012). Paraoxonase 1 and homocysteine metabolism. Amino Acids, 43(4), 1405-1417. DOI: 10.1007/s00726-012-1321-z

[19] Rosta, V., Trentini, A., Passaro, A., Zuliani, G., Sanz, J. M., Bosi, C., … & Cervellati, C. (2020). Sex Difference Impacts on the Relationship between Paraoxonase-1 (PON1) and Type 2 Diabetes. Antioxidants, 9(8), 683. DOI:10.3390/antiox9080683

[20] Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., & Fuster, V. (2020). Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol., 76(25), 2982-3021. DOI: 10.1016/j.jacc.2020.11.010

[21] Shunmoogam, N., Naidoo, P., & Chilton, R. (2018). Vascular Health and Risk Management Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance. Vascular Health and Risk Management, 14, 137-143. DOI: 10.2147/VHRM.S165173

[22] Somani, Y. B., Pawelczyk, J. A., De Souza, M. J., Kris-Etherton, P. M., & Proctor, D. N. (2019). Aging women and their endothelium: probing the relative role of estrogen on vasodilator function Am J Physiol Heart Circ Physiol., 317(2), H395-H404. DOI: 10.1152/ajpheart.00430.2018

[23] Trentini, A., Bellini, T., Bonaccorsi, G., Cavicchio, C., Hanau, S., Passaro, A., & Cervellati, C. (2019). Sex difference: an important issue to consider in epidemiological and clinical studies dealing with serum paraoxonase-1. J Clin Biochem Nutr., 64(3), 250-256. DOI: 10.3164/jcbn.18-73

[24] Wu, J., Dai, F., Li, Ch., & Zou, Yu. (2020). Gender Differences in Cardiac Hypertrophy. Cardiovasc Transl Res., 13(1), 73-84. DOI: 10.1007/s12265-019-09907-z

[25] Yuksel, M., Yildiz, A., Tekbas, E., Gunduz, E., Ekinci, A., Bilik, M. Z., … & Atilgan, Z. (2015). Paraoxonase and Arylesterase Activities in Dipper and Non-Dipper Prehypertensive Subjects. Medicine (Baltimore), 94(17), 786. DOI: 10.1097/MD.0000000000000786
Published
2021-06-24
How to Cite
Pentiuk, L. O., & Pentiuk, N. O. (2021). Paraoxonase in women with hypertension of different reproductive age. Relationship with cardio-metabolic risk factors. Reports of Vinnytsia National Medical University, 25(2), 252-257. https://doi.org/https://doi.org/10.31393/reports-vnmedical-2021-25(2)-11